Leptoprol (Leuprorelin)

Leuprorelin mimics natural GnRH and binds to pituitary GnRH receptors. After an initial stimulation, continuous exposure leads to receptor down‑regulation, causing a sustained fall in LH and FSH secretion. The resulting drop in testosterone and estrogen levels reduces hormonal drive for the targeted conditions.

The specific dose and dosing interval of leuprorelin are determined by the prescribing clinician based on the indication, patient characteristics, and treatment goals. Dosing may range from monthly to quarterly administrations, and the prescriber will select the appropriate regimen and formulation for each individual.

Leuprorelin is classified as contraindicated for use in pregnant women because it can suppress fetal hormone production. Its safety during breastfeeding has not been established, and the drug is generally avoided in nursing mothers. Women of childbearing potential should use effective contraception during treatment.

To request Leptoprol, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Leuprorelin is one of several GnRH agonists, such as goserelin and triptorelin, sharing a common mechanism of pituitary down‑regulation. Differences lie mainly in formulation, dosing frequency and pharmacokinetic profile; leuprorelin is available in both short‑acting and long‑acting injectable forms, allowing flexible scheduling compared with some alternatives that may require more frequent dosing.

Leptoprol should be stored at 2‑8 °C in a refrigerator. Keep the vials in the original packaging to protect from light, and avoid freezing or shaking the solution. If temporary exposure to room temperature occurs, the product may be used within the time frame specified in the labeling.

Leptoprol is supplied as a sterile solution for subcutaneous injection. The injection is typically performed by a healthcare professional in a clinical setting, using aseptic technique. The site is usually the abdomen or thigh, and the volume administered depends on the prescribed dose. Patients should follow the prescriber’s instructions for injection frequency.

The most serious risks include cardiovascular events such as myocardial infarction, severe allergic reactions (anaphylaxis), significant bone density loss leading to fractures, and rare cases of pituitary apoplexy. Patients should be monitored regularly for signs of these complications, and therapy should be discontinued if severe adverse events occur.

Leuprorelin is contraindicated in individuals with known hypersensitivity to leuprorelin or any excipients, pregnant women, and patients with uncontrolled cardiovascular disease. Caution is also advised for those with severe osteoporosis, active liver disease, or a history of thromboembolic events. The prescribing clinician must evaluate each patient’s medical history before initiating therapy.